Dasom (Caroline) Lee, MD, details the safety results of second-line axicabtagene ciloleucel in real-world patients with relapsed/refractory LBCL.
Dasom (Caroline) Lee, MD
Advertisement
Dasom (Caroline) Lee, MD, is a fellow in the Hematology and Medical Oncology Fellowship Program at Stanford Medicine, Stanford Health Care.
Articles by Dasom (Caroline) Lee, MD
Dasom (Caroline) Lee, MD, discusses real-world early outcomes of treatment with second-line axi-cel in relapsed/refractory large B-cell lymphoma.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
Oncology Fellows Presents a New Drug Cheat Sheet for Fellows
3
Third NDA for Rivoceranib/Camrelizumab Is Resubmitted to FDA for Unresectable HCC
4
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
5